Polatuzumab Vedotin-piiq

1 1

Selleck Chemicals

D4012-1MG

€953,00 EUR
€953,00 EUR
Sale Sold out
Taxes included. Shipping calculated at checkout.
Size
View full details

Polatuzumab Vedotin-piiq is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE).

Product overview

It is used for research involving relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The product background identifies the antibody component, target antigen and payload or linker architecture where these details are supplied. This ADC context supports comparison of antigen recognition, payload conjugation and cellular uptake behavior in controlled assay systems, especially when researchers need to distinguish conjugated biologics from unconjugated antibodies or standalone small molecules.

Laboratory context

The listed workflow context supports binding and uptake-oriented laboratory studies where a defined antibody component, cellular target and conjugated payload are relevant to assay planning, including cell-surface binding, cell-uptake and protein-binding experiments, within oncology research.

Research Area:
Oncology
Application:
Cell Surface Binding • Cell Uptake Studies • Protein Binding
Formulation:
100 mM Pro-Ac, 20mM Arg, pH5.0
CAS No.:
1313206-42-6
Storage Temperature:
-20°C

For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.

The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.